

| Staphylococcus intermedius ear | 2012 Canine | 2013 Canine (Jan-early Dec) | 2014 Canine |
|--------------------------------|--------------------------|-----------------------------|--------------------------|
| Antimicrobial | % Susceptible (n tested) | % Susceptible (n tested) | % Susceptible (n tested) |
| Amikacin | 78.1% (n=32) | 79.3% (n=29) | 61.40% (n=57) |
| Amoxicillin/Clavulanate | 68.8% (n=32) | 82.8% (n=29) | 71.93% (n=57) |
| Ampicillin | 22% (n=32) | 17.2% (n=29) | 17.54% (n=57) |
| Cefazolin | 68.8% (n=32) | 86.2% (n=29) | 71.93% (n=57) |
| Cefocefiv | 68.8% (n=32) | 86.2% (n=29) | 66.67% (n=57) |
| Cefpodoxime | 68.8% (n=32) | 86.2% (n=29) | 71.93% (n=57) |
| Ceftiofur | 78.9% (n=19) | N/A | N/A |
| Cephalothin | N/A | N/A | N/A |
| Chloramphenicol | 100% (n=32) | 82.8% (n=29) | 80.70% (n=57) |
| Ciprofloxacin | N/A | N/A | N/A |
| Clindamycin | 78.1% (n=32) | 75.9% (n=29) | 68.42% (n=57) |
| Doxycycline | 62.5% (n=32) | 75.9% (n=29) | 64.91% (n=57) |
| Enrofloxacin | 78.1% (n=32) | 86.2% (n=29) | 59.65% (n=57) |
| Erythromycin | 78.1% (n=32) | 72.4% (n=29) | 68.42% (n=57) |
| Gentamicin | 68.8% (n=32) | 60% (n=29) | 45.61% (n=57) |
| Levofloxacin | N/A | N/A | N/A |
| Linezolid | N/A | N/A | N/A |
| Marbofloxacin | 78.1% (n=32) | 93.1% (n=29) | 73.68% (n=57) |
| Mupirocin | 100% (n=5) | 100% (n=5) | N/A |
| Neomycin | N/A | N/A | N/A |
| Orbifloxacin | N/A | N/A | N/A |
| Oxacillin | 68.8% (n=32) | 86.2% (n=29) | 66.67% (n=57) |
| Penicillin | 21.9% (n=32) | 15.6% (n=32) | 17.54% (n=57) |
| Rifampin | 100% (n=32) | 100% (n=29) | 94.75% (n=57) |
| Tetracycline | N/A | N/A | N/A |
| Trimethoprim/Sulfamethoxazole | 75% (n=32) | 89.7% (n=29) | 73.68% (n=57) |
| Vancomycin | N/A | N/A | N/A |

| S. intermedius skin | 2011 Canine | 2012 Canine | 2013 Canine | 2014 Canine |
|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Antimicrobial | % Susceptible (n tested) | % Susceptible (n tested) | % Susceptible (n tested) | % Susceptible (n tested) |
| Amikacin | N/A | 80% (n=156) | 77% (n=151) | 88% (n=220) |
| Ampicillin | 7% (n=4) | 19% (n=37) | 19% (n=37) | 21% (n=220) |
| Cefazolin | N/A | 76% (n=149) | 72% (n=140) | 78% (n=220) |
| Cefovecin | N/A | 75% (n=147) | 72% (n=140) | 78% (n=220) |
| Cefpodoxime | N/A | 75% (n=147) | 72% (n=140) | 78% (n=220) |
| Ceftiofur | N/A | 78% (n=69) | N/A | N/A |
| Cephalothin | 100% (n=4) | N/A | N/A | N/A |
| Chloramphenicol | 92% (n=55) | 93% (n=185) | 89% (n=174) | 90% (n=220) |
| Clavamox | 100% (n=61) | 76% (n=149) | 72% (n=140) | 78% (n=220) |
| Clindamycin | 83% (n=50) | 74% (n=146) | 65% (n=127) | 70% (n=220) |
| Enrofloxacin | 84% (n=51) | 84% (n=164) | 76% (n=149) | 80% (n=220) |
| Erythromycin | N/A | 74% (n=146) | 64% (n=125) | 70% (n=220) |
| Gentamicin | 90% (n=55) | 72% (n=143) | 71% (n=138) | 80% (n=220) |
| Marbofloxacin | 98% (n=60) | 90% (n=178) | 88% (n=172) | 89% (n=220) |
| Mupirocin | 100% (n=58) | 100% (n=180) | 99% (n=177) | 100% (n=131) |
| Oxacillin | 100% (61) | 76% (n=151) | 72% (n=140) | 78% (n=220) |
| Penicillin | 7% (n=4) | 19% (n=37) | 19% (n=37) | 21% (n=220) |
| Rifampin | N/A | 96% (n=190) | 100% (n=195) | 100% (n=220) |
| Tetracycline | 59% (n=36) | 65% (n=128) | 61% (n=118) | 63% (n=220) |
| Ticaricillin | N/A | 81% (n=166) | 75% (n=117) | N/A |
| Ticaricillin/Clavulanate | N/A | 89% (n=184) | 83% (n=131) | N/A |
| Trimethoprim/Sulphamethoxazole | 75% (n=46) | 78% (n=188) | 72% (n=139) | 79% (n=220) |



VMC ANTIBIOGRAM 2011-2014

A reference guide for clinicians choosing appropriate antibiotics prior to obtaining culture and sensitivity results.

Susceptibilities were determined using isolation information from Marshfield Laboratories.

This antibiogram can serve as a valuable tool in guiding antimicrobial therapy, but please consider patient factors, such as previous infection history and antibiotic use.

Remember the hospital antibiogram reflects our patient population, not the general community.

For additional guidance on UTI or pyoderma treatment, please see published guidelines.

university of minnesota veterinary medical center
1365 gortner avenue, st. paul, mn 55108
612-626-VETS (8387)

www.umnvets.com

| E. coli Urine | 2011 | 2011 | 2012 | 2012 | 2013 | 2013 | 2014 | 2014 |
|------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| | Canine | Feline | Canine | Feline | Canine | Feline | Canine | Feline |
| Antimicrobial | % Susceptible | % Susceptible | % Susceptible | % Susceptible | % Susceptible | % Susceptible | % Susceptible | % Susceptible |
| Amikacin | N/A | N/A | 100% (n=206) | 100% (n=58) | 100% (n=156) | 100% (n=47) | 100% (n=172) | 100% (n=53) |
| Ampicillin | 63% (n=78) | 68% (n=17) | 80% (n=166) | 64% (n=38) | 73% (n=115) | 77% (n=36) | 75% (n=173) | 79% (n=53) |
| Cefovecin | 85% (n=104) | 96% (n=24) | 92% (n=191) | 85% (n=50) | 89% (n=140) | 96% (n=45) | 88% (n=172) | 96% (n=53) |
| Cefpodoxime | N/A | N/A | 92% (n=189) | 88% (n=51) | 89% (n=139) | 94% (n=44) | 88% (n=172) | 94% (n=53) |
| Ceftiofur | 87% (n=107) | 100% (n=25) | 95% (n=119) | 81% (n=25) | N/A | N/A | N/A | N/A |
| Cephalothin | 66% (n=81) | 80% (n=20) | N/A | N/A | N/A | N/A | N/A | N/A |
| Chloramphenicol | N/A | N/A | 92% (n=189) | 91% (n=53) | 96% (n=150) | 94% (n=44) | 92% (n=172) | 96% (n=53) |
| Clavamox | 78% (n=96) | 96% (n=24) | 88% (n=182) | 85% (n=49) | 83% (n=131) | 85% (n=40) | 88% (n=172) | 92% (n=53) |
| Clindamycin | N/A | N/A | 0% (n=0) | 0% (n=0) | 0% (n=0) | 0% (n=0) | 0% (n=172) | 0% (n=53) |
| Enrofloxacin | 83% (n=102) | 96% (n=24) | 93% (n=194) | 86% (n=51) | 87% (n=136) | 100% (n=47) | 85% (n=172) | 98% (n=53) |
| Gentamicin | 92% (n=113) | 100% (n=25) | 94% (n=195) | 93% (n=55) | 92% (n=145) | 100% (n=47) | 95% (n=172) | 98% (n=53) |
| Marbofloxacin | 85% (n=104) | 96% (n=24) | 93% (n=194) | 93% (n=55) | 89% (n=139) | 100% (n=47) | 86% (n=172) | 98% (n=53) |
| Neomycin | 93% (n=114) | 100% (n=25) | N/A | N/A | N/A | N/A | N/A | N/A |
| Orbifloxacin | 82% (n=101) | 96% (n=24) | N/A | N/A | N/A | N/A | N/A | N/A |
| Tetracycline/ Doxycycline | 80% (n=99) | 92% (n=23) | 86% (n=178) | 81% (n=47) | 89% (n=140) | 91% (n=43) | 86% (n=172) | 98% (n=53) |
| Ticarillin | N/A | N/A | 81% (n=166) | 66% (n=38) | 75% (n=117) | 79% (n=37) | 77% (n=172) | 83% (n=53) |
| Ticarillin/ Clavulanate | N/A | N/A | 89% (n=184) | 79% (n=46) | 83% (n=131) | 87% (n=41) | 90% (n=172) | 89% (n=53) |
| Trimethoprim/ Sulphamethoxazole | 85% (n=104) | 96% (n=24) | 90% (n=188) | 92% (n=54) | 88% (n=138) | 96% (n=45) | 89% (n=172) | 83% (n=53) |

| Pseudomonas aeruginosa ear | 2011 | 2012 | 2013 | 2014 |
|-------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| | Canine | Canine | Canine (Jan-early Dec) | Canine |
| Antimicrobial | % Susceptible (n tested) | % Susceptible (n tested) | % Susceptible (n tested) | % Susceptible (n tested) |
| Amikacin | 76.5% (n=34) | 94.1% (n=51) | 95.8% (n=48) | 91.67% (n=24) |
| Amoxicillin/Clavulanate | N/A | 0% (n=52) | 0% (n=48) | 0% (n=24) |
| Ampicillin | N/A | 0% (n=52) | 0% (n=48) | 0% (n=24) |
| Cefazolin | N/A | 0% (n=52) | 0% (n=48) | 0% (n=24) |
| Cefovecin | N/A | 0% (n=52) | 0% (n=48) | 0% (n=24) |
| Cefoperazone | N/A | 0% (n=52) | 0% (n=48) | 0% (n=24) |
| Ceftiofur | N/A | 0% (n=33) | N/A | N/A |
| Chloramphenicol | 0% (n=2) | 100% (n=1) | 0% (n=2) | N/A |
| Ciprofloxacin | 79.4% (n=34) | N/A | N/A | N/A |
| Clindamycin | N/A | 0% (n=52) | 0% (n=48) | 0% (n=24) |
| Colistin | N/A | N/A | N/A | N/A |
| Doxycycline | N/A | 0% (n=52) | 0% (n=48) | 0% (n=24) |
| Enrofloxacin | 26.5% (n=34) | 41.2% (n=51) | 52.1% (n=48) | 45.83% (n=24) |
| Gentamicin | 64.7% (n=34) | 74.5% (n=51) | 83.3% (n=48) | 62.5% (n=24) |
| Imipenem | 100% (n=34) | 100% (n=51) | 100% (n=48) | 83.33% (n=24) |
| Marbofloxacin | 79.4% (n=34) | 60.8% (n=51) | 68.8% (n=48) | 58.33% (n=24) |
| Neomycin | 23.5% (n=34) | N/A | N/A | N/A |
| Norfloxacin | 79.4% (n=34) | N/A | N/A | N/A |
| Orbifloxacin | 14.7% (n=34) | N/A | N/A | N/A |
| Piperacillin | 100% (n=34) | N/A | N/A | N/A |
| Ticarillin | 97.1% (n=34) | 92.2% (n=51) | 83.3% (n=48) | 91.67% (n=24) |
| Ticarillin/Clavulanate | N/A | 92.2% (n=51) | 85.4% (n=48) | 95.83% (n=24) |
| Tobramycin | 97.1% (n=34) | N/A | N/A | N/A |
| Trimethoprim/Sulfamethoxazole | N/A | 0% (n=51) | 0% (n=48) | 0% (n=24) |